biochemo + bevacizumab + ipilimumab

This is a combination regimen consisting of "biochemo" (a term typically referring to a combination of cytotoxic chemotherapies and/or biologic agents, often used in melanoma), plus bevacizumab (a monoclonal antibody targeting vascular endothelial growth factor A, VEGF-A), and ipilimumab (a monoclonal antibody targeting cytotoxic T-lymphocyte antigen 4, CTLA-4). - **Biochemo** regimens vary but commonly include drugs such as dacarbazine, cisplatin, vinblastine, and sometimes interleukin-2 or interferon-alpha. The precise composition should be specified for clinical use. - **Bevacizumab** inhibits angiogenesis by binding VEGF-A and preventing it from activating its receptors on endothelial cells. - **Ipilimumab** is an immune checkpoint inhibitor that blocks CTLA-4 on T cells, enhancing the immune response against tumor cells[5][6][7]. This multi-agent regimen aims to combine direct cytotoxic effects (from chemotherapy), antiangiogenic effects (from bevacizumab), and immunomodulatory activity (from ipilimumab) for synergistic antitumor efficacy.